CN111094313A - 盐酸伊达比星一水合物的晶型 - Google Patents

盐酸伊达比星一水合物的晶型 Download PDF

Info

Publication number
CN111094313A
CN111094313A CN201880057475.0A CN201880057475A CN111094313A CN 111094313 A CN111094313 A CN 111094313A CN 201880057475 A CN201880057475 A CN 201880057475A CN 111094313 A CN111094313 A CN 111094313A
Authority
CN
China
Prior art keywords
idarubicin hydrochloride
crystalline form
hydrochloride monohydrate
crude
idarubicin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880057475.0A
Other languages
English (en)
Other versions
CN111094313B (zh
Inventor
徐丹
葛书旺
苏进财
吴舰
王华萍
柴雨柱
朱春霞
田舟山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN111094313A publication Critical patent/CN111094313A/zh
Application granted granted Critical
Publication of CN111094313B publication Critical patent/CN111094313B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了盐酸伊达比星一水合物的新晶型，新晶型的制备方法，包含该新晶型的药物组合物以及其在预防和/或治疗肿瘤疾病中的医药用途。

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN201880057475.0A 2017-09-22 2018-09-21 盐酸伊达比星一水合物的晶型 Active CN111094313B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017108644123 2017-09-22
CN201710864412 2017-09-22
PCT/CN2018/107008 WO2019057165A1 (zh) 2017-09-22 2018-09-21 盐酸伊达比星一水合物的晶型

Publications (2)

Publication Number Publication Date
CN111094313A true CN111094313A (zh) 2020-05-01
CN111094313B CN111094313B (zh) 2022-07-05

Family

ID=65809536

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880057475.0A Active CN111094313B (zh) 2017-09-22 2018-09-21 盐酸伊达比星一水合物的晶型

Country Status (2)

Country Link
CN (1) CN111094313B (zh)
WO (1) WO2019057165A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN85103835A (zh) * 1985-05-13 1986-11-12 法米塔利·卡洛·埃尔巴有限公司 制备4-脱甲氧-道诺红菌素的改进方法
PL195417B1 (pl) * 2000-10-10 2007-09-28 Inst Farmaceutyczny Korzystna farmaceutycznie forma krystaliczna hydratu chlorowodorku idarubicyny, sposób jej otrzymywania i zawierające ją środki farmaceutyczne
CN103906757A (zh) * 2011-09-19 2014-07-02 贺利氏贵金属有限责任两合公司 盐酸伊达比星的结晶

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN85103835A (zh) * 1985-05-13 1986-11-12 法米塔利·卡洛·埃尔巴有限公司 制备4-脱甲氧-道诺红菌素的改进方法
PL195417B1 (pl) * 2000-10-10 2007-09-28 Inst Farmaceutyczny Korzystna farmaceutycznie forma krystaliczna hydratu chlorowodorku idarubicyny, sposób jej otrzymywania i zawierające ją środki farmaceutyczne
CN103906757A (zh) * 2011-09-19 2014-07-02 贺利氏贵金属有限责任两合公司 盐酸伊达比星的结晶

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
蒲刚等: "盐酸伊达比星的半合成研究", 《中国抗生素杂志》 *

Also Published As

Publication number Publication date
WO2019057165A1 (zh) 2019-03-28
CN111094313B (zh) 2022-07-05

Similar Documents

Publication Publication Date Title
EP3555061B1 (en) Solid state forms of apalutamide
CN107531646B (zh) 尿嘧啶化合物的结晶
CN114728899B (zh) 新型三苯基化合物盐
EP2710015B1 (en) Polymorph of rifaximin and process for the preparation thereof
KR102522895B1 (ko) Jak 키나아제 억제제 바이설페이트의 결정형 및 이의 제조방법
AU2002253698B2 (en) Clathrate of azithromycin hydrate with 1,2-propyleneglycol, method for the manufacture thereof and pharmaceutical composition comprising same
EP3159349B1 (en) Lobaplatin crystal, preparation method and pharmaceutical application
WO2018019188A1 (zh) 核苷氨基磷酸酯类前药的多晶型及其制备方法
CN111094313B (zh) 盐酸伊达比星一水合物的晶型
AU2017329753B2 (en) Crystalline polymorphic form of 3-hydroxy-4,5-bis-benzyloxy-6-benzyloxymethyl-2-phenyl-2-oxo-2lambda5-(1,2)oxaphosphinane
CN113444073A (zh) 吗啉基喹唑啉类化合物的晶型ⅲ、其制备方法及应用
WO2008102374A1 (en) Amorphous form of docetaxel
JP2002515493A (ja) 熱的に安定なトリメトレキサートおよびその製造プロセス
CN113045554A (zh) 一种非索替尼晶型及其制备方法
CN112125910A (zh) 一种阿伐普替尼晶型及其制备方法
CN104693271A (zh) 一种硼替佐米晶型、制备方法及其药物组合物和用途
WO2017215521A1 (zh) Plx3397的盐酸盐晶型及其制备方法和用途
CN113698356B (zh) 新型parp抑制剂的稳定晶型及其制备方法
CN106336363A (zh) 一种沙芬酰胺甲磺酸盐晶型c及其制备方法
US20080139490A1 (en) Crystalline forms of valrubicin and processes for their preparation
CN106749048B (zh) 一种盐酸厄洛替尼晶型化合物及其制备方法
CN113754684A (zh) 一种塞尔帕替尼晶型及其制备方法
CN113801021A (zh) 绿原酸钠水合物及其应用
JP2023543055A (ja) テガビビントの結晶形態、調製方法、及びその使用
CN116120301A (zh) 一种化合物的甲磺酸盐晶型、药物组合物及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant